An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities
Latest Information Update: 12 Apr 2026
At a glance
- Drugs Danicamtiv (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions; Proof of concept
- Sponsors Bristol-Myers Squibb; MyoKardia
Most Recent Events
- 17 Mar 2026 According to a Kardigan media release, data from this study will be presented by Neal Lakdawala, M.D., in a poster presentation on Monday, March 30, 2026 at the American College of Cardiology's Annual Scientific Session & Expo (ACC.26), taking place on March 28-30, 2026 in New Orleans.
- 06 Jan 2026 According to Kardigan media release, results from this trial were presented at the American Heart Association Scientific Sessions 2025.
- 29 Sep 2025 According to Kardigan media release, the company announced that positive Phase 2a clinical trial data were presented in a late-breaking oral session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 and simultaneously published in The Journal of the American College of Cardiology (JACC).